Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 2225, 2005; 10.1373/clinchem.2005.059618
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Engvall, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Engvall, E.
Related Collections
Right arrow Animal Clinical Chemistry
Right arrow History
Right arrow Point-of-Care Testing
Right arrow Infectious Disease
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2005;51:2225.)
© 2005 American Association for Clinical Chemistry, Inc.

Perspectives

Perspective on the Historical Note on EIA/ELISA by Dr. R.M. Lequin

Eva Engvall

The Burnham Institute, La Jolla, CA

Address for correspondence: The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92067. E-mail eengvall@burnham.org.

The first 20% of the full text of this article appears below.

I am pleased and humbled to see Dr. Lequin write about my work on ELISA in his historical note (1). Unfortunately, my thesis advisor, mentor, and friend, Peter Perlmann, cannot read it, as he recently passed away. One summer day 35 years ago, I knocked on the door of Professor Perlmann’s office at Stockholm University to ask him if I could be a graduate student in his department. He accepted me into his laboratory, and we agreed that I would try to develop an immunoassay based on enzymatic readout. After talking it over with Peter and reading the literature, I combined the format of RIA (2), enzyme labeling of antibodies(3), and the coating of plastic with proteins (4) in my experiments. From the very beginning, I referred to the assay I was trying to develop as ELISA, and that acronym stuck. We were convinced that enzyme immunoassays (EIAs) were going to . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.